107.521 articles found

Therapeutic potential of Canna edulis RS3-resistant starch in alleviating neuroinflammation and apoptosis in a Parkinson's disease rat model

He QK, Wang XY, Huwei, Cai J, Chen P, Liu M, Wu YH.

Heliyon · 2024-09-01

132 Behavioural change for Parkinson’s Disease: A randomised controlled feasibility study to promote physical activity and exercise adherence among people with Parkinson’s Disease

Check source for author details

European journal of public health · 2024-09-01

Noradrenergic modulation of saccades in Parkinson's disease.

Orlando IF, Hezemans FH, Ye R, Murley AG, Holland N, Regenthal R, Barker RA, Williams-Gray CH, Passamonti L, Robbins TW, Rowe JB, O'Callaghan C.

Brain Commun · 2024-09-01

DOI: 10.1093/braincomms/fcae297PMID: 39464213

Correction: Clinimetrics and feasibility of the Italian version of the Frontal Assessment Battery (FAB) in non-demented Parkinson's disease patients.

Aiello EN, D'Iorio A, Solca F, Torre S, Bonetti R, Scheveger F, Colombo E, Maranzano A, Maderna L, Morelli C, Doretti A, Amboni M, Vitale C, Verde F, Ferrucci R, Barbieri S, Zirone E, Priori A, Pravettoni G, Santangelo G, Silani V, Ticozzi N, Ciammola A, Poletti B.

J Neural Transm (Vienna) · 2024-09-01

DOI: 10.1007/s00702-023-02690-xPMID: 37665386

Correction to: Role of dopamine agonists in Parkinson's disease therapy.

Woitalla D, Buhmann C, Hilker-Roggendorf R, Höglinger G, Koschel J, Müller T, Weise D.

J Neural Transm (Vienna) · 2024-09-01

DOI: 10.1007/s00702-023-02695-6PMID: 37702775

Sleep macro-architecture in patients with Parkinson's disease does not change during the first night of neurostimulation in a pilot study.

Das R, Gliske SV, West LC, Summers MO, Tang S, Hirt L, Maroni D, Halpern CH, Thompson JA, Kushida CA, Abosch A.

J Clin Sleep Med · 2024-09-01

DOI: 10.5664/jcsm.11180PMID: 38652493

Advancing Parkinson's disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells.

Clark BJ, Lelos MJ, Loring JF.

Stem Cells · 2024-09-01

DOI: 10.1093/stmcls/sxae042PMID: 38902932

Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy.

Adams JW, Kirsch D, Calderazzo SM, Tuz-Zahra F, Tripodis Y, Mez J, Alosco ML, Alvarez VE, Huber BR, Kubilus C, Cormier KA, Nicks R, Uretsky M, Nair E, Kuzyk E, Aytan N, Cherry JD, Crary JF, Daneshvar DH, Nowinski CJ, Goldstein LE, Dwyer B, Katz DI, Cantu RC, Stern RA, McKee AC, Stein TD.

JAMA Neurol · 2024-09-01

DOI: 10.1001/jamaneurol.2024.2166PMID: 39008284

Substantia(l) Impacts of Contact Sport Play and Parkinsonism.

Asken BM, Scholz SW, Prokop S.

JAMA Neurol · 2024-09-01

DOI: 10.1001/jamaneurol.2024.2162PMID: 39008329

Assessing the prevalence and risk of tooth wear in Parkinson's disease: A narrative review.

Verhoeff MC, Wetselaar P, Lobbezoo F.

Dent Med Probl · 2024-09-01

DOI: 10.17219/dmp/183842PMID: 39028034

Fecal Microbiome Transplants For Parkinson Disease.

Sampson TR.

JAMA Neurol · 2024-09-01

DOI: 10.1001/jamaneurol.2024.2293PMID: 39073794

Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial.

Scheperjans F, Levo R, Bosch B, Lääperi M, Pereira PAB, Smolander OP, Aho VTE, Vetkas N, Toivio L, Kainulainen V, Fedorova TD, Lahtinen P, Ortiz R, Kaasinen V, Satokari R, Arkkila P.

JAMA Neurol · 2024-09-01

DOI: 10.1001/jamaneurol.2024.2305PMID: 39073834